| Identification | Back Directory | [Name]
PF 477736 | [CAS]
952021-60-2 | [Synonyms]
PF-736
CS-237
PF 477736
PF0044736
PF0477736
PF-0044736
PF-00477736
PF-736,PF-00477736
PF 477736 USP/EP/BP
PF 477736(PF-0044736)
PF 477736 - PF 00477736
NDEXUOWTGYUVGA-LJQANCHMSA-N
PF 477736;PF-477736;PF477736
(R)-2-Amino-2-cyclohexyl-N-(2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-5,6-dihydro-1H-[1,2]diazepino[4
α-amino-n-[5,6-dihydro-2-(1-methyl-1h-pyrazol-4-yl)-6-oxo-1h-pyrrolo[4,3,2-ef][2,3]benzodiazepin-8-yl]-cyclohexaneacetamide
(R)-2-AMINO-2-CYCLOHEXYL-N-[2-(1-METHYL-1H-PYRAZOL-4-YL)-6-OXO-5,6-DIHYDRO-1H-[1,2]DIAZEPINO[4,5,6-CD]INDOL-8-YL]-ACETAMIDE
(2R)-2-Amino-2-cyclohexyl-N-[2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl]-acetamide
(αR)-α-AMino-N-[5,6-dihydro-2-(1-Methyl-1H-pyrazol-4-yl)-6-oxo-1H-pyrrolo[4,3,2-ef][2,3]benzodiazepin-8-yl]cyclohexaneacetaMide
Cyclohexaneacetamide, α-amino-N-[5,6-dihydro-2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1H-pyrrolo[4,3,2-ef][2,3]benzodiazepin-8-yl]-, (αR)-
(alphaR)-alpha-Amino-N-[5,6-dihydro-2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1H-pyrrolo[4,3,2-ef][2,3]benzodiazepin-8-yl]cyclohexaneacetamide
(2R)-2-aMino-2-cyclohexyl-N-[2-(1-Methyl-1H-pyrazol-4-yl)-9-oxo-3,10,11-triazatricyclo[6.4.1.0^{4,13}]trideca-1,4(13),5,7,11-pentaen-6-yl]acetaMide
(alphaR)-alpha-Amino-N-[5,6-dihydro-2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1H-pyrrolo[4,3,2-ef][2,3]benzodiazepin-8-yl]cyclohexaneacetamide PF-477736 | [Molecular Formula]
C22H24N7O2 | [MDL Number]
MFCD16038847 | [MOL File]
952021-60-2.mol | [Molecular Weight]
418.472 |
| Chemical Properties | Back Directory | [density ]
1.56 | [storage temp. ]
2-8°C | [solubility ]
DMSO: ≥20mg/mL | [form ]
powder | [pka]
11.79±0.20(Predicted) | [color ]
yellow | [InChIKey]
NDEXUOWTGYUVGA-LJQANCHMSA-N |
| Hazard Information | Back Directory | [Description]
Checkpoint kinase 1 (Chk1) regulates S and G2-M phase cell cycle checkpoints in response to DNA damage. PF-477736 is an ATP-competitive inhibitor of Chk1 with a Ki value of 0.49 nM that demonstrates 100-fold selectivity over Chk2.1 When used in combination with various chemotherapeutics, PF-477736 abrogates DNA damage-induced cell cycle arrest, potentiating the antiproliferative effects of these compounds in tumor cell lines and xenografts.1,2,3 | [Uses]
Checkpoint kinase 1 (Chk1) regulates S and G2-M phase cell cycle checkpoints in response to DNA damage. PF-477736 is an ATP-competitive inhibitor of Chk1 with a Ki value of 0.49 nM that demonstrates 100-fold selectivity over Chk2. When used in combination with various chemotherapeutics, PF-477736 abrogates DNA damage-induced cell cycle arrest, potentiating the antiproliferative effects of these compounds in tumor cell lines and xenografts.[Cayman Chemical] | [Uses]
P293850 is a selective checkpoint kinase 1 (Chk1) inhibitor (Ki values are 0.49 and 47 nM for Chk1 and Chk2 respectively). Abrogates cell cycle arrest at S and G2-M checkpoints; sensitizes cells to DNA damage. | [Definition]
ChEBI:PF-00477736 is a diazepinoindole that is 8-amino-4,5-dihydro-6H-[1,2]diazepino[4,5,6-cd]indol-6-one which is substituted at position 2 by a 1-methylpyrazol-4-yl group and in which the amino group at position 8 has undergone condensation with the carboxy group of (2R)-2-cyclohexylglycine to give the corresponding carboxamide. It is an inhibitor of checkpoint kinase 1 (Chk 1). It has a role as an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor and an antineoplastic agent. It is an amino acid amide, a member of pyrazoles and a diazepinoindole. | [Biochem/physiol Actions]
PF-477736 may be effectively used to resensitize platinum resistant ovarian cancer cells. PF-477736 alone or in combination with other chemotherapeutic agents may be used to treat triple-negative breast cancer. | [storage]
Store at -20°C | [References]
[1] blasina a1, hallin j, chen e, arango me, kraynov e, register j, grant s, ninkovic s, chen p, nichols t, o'connor p, anderes k. breaching the dna damage checkpoint via pf-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. mol cancer ther. 2008 aug;7(8):2394-404. |
|
|